Sun Pharmaceutical Industries has received an approval from US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for generic version of Zyprexa Zydis, Olanzapine ODT, 5 mg, 10 mg, 15 mg and 20 mg.
These generic Olanzapine orally disintegrating tablets, 5 mg, 10 mg, 15 mg and 20 mg are therapeutic equivalents of Eli Lilly’s Zyprexa Zydis tablets. Olanzapine orally disintegrating tablets have annual sale of approximately $360 million in the US.
Olanzapine OD tablets are indicated for the treatment of schizophrenia, bipolar I disorder (manic or mixed episodes).
Sun Pharmaceutical Industries manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: